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Abstract	
	Pregnancy	leads	to	adaptations	of	the	maternal	metabolism	and	immune	system.	Increased	 levels	 of	 steroid	 hormones	 induce	 insulin	 resistance,	 leading	 to	 a	glucose	gradient	from	the	mother	to	the	fetus,	which	is	modulated	by	changes	in	insulin	secretion.	The	maternal	adaptive	and	innate	immune	systems	are	modified	to	accept	the	fetus,	a	semi-allograft.		Gestational	 diabetes	 mellitus	 occurs	 in	 genetically	 predisposed	 women	 and	 is	associated	with	obesity	 and	 ageing.	 It	 is	 characterized	 by	 a	 further	 increase	of	insulin	 resistance	 and	 insufficient	 insulin	 secretion.	 The	 immune	 system	 of	women	with	gestational	diabetes	is	tilted	toward	inflammation,	e.g.	with	higher	interleukin-1β	(IL-1β)	expression	in	the	adipose	tissues	and	the	placenta,	and	with	higher	levels	of	circulating	IL-1β.	We	 investigated	 the	 role	 of	 IL-1β	 in	 glucose	 metabolism	 during	 pregnancy	 in	young	chow-fed	mice,	and	older	mice	fed	high-fat	diet.	To	study	the	effect	of	IL-1β,	a	neutralizing	anti-IL-1β	antibody	and	IL-1β-deficient	mice	were	used.	Pregnancy	 impaired	glucose	 tolerance	and	 increased	circulating	 IL-1β	and	 Il1b	gene	 expression	 in	 the	 uterus	 of	 chow-fed	 mice	 and	 of	 high-fat	 diet-fed	 mice	compared	 to	 their	 respective	 non–pregnant	 controls.	 Antagonizing	 IL-1β	improved	glucose	tolerance	of	pregnant	chow-fed	mice	and	of	older	high-fat	diet-fed	mice.	Similarly,	pregnant	IL-1β	KO	mice	showed	improved	glucose	tolerance	compared	to	pregnant	littermate	control	mice,	supporting	the	hypothesis	that	IL-1β	plays	a	role	in	pregnancy-induced	glucose	intolerance.	Further,	antagonizing	IL-1β	reduced	serum	levels	of	several	steroid	hormones	in	healthy	pregnant	mice.		We	 conclude,	 that	 IL-1β	 contributes	 to	 the	 impairment	 of	 glucose	metabolism	during	pregnancy,	possibly	via	modulation	of	steroid	hormones.					
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List	of	abbreviations	AUC	 area	under	the	curve	cDNA	 complementary	deoxyribonucleic	acid	CRP	 C-reactive	protein	Ct	 threshold	cycle		CYP11B1,	CYP11B2	 steroid-11β-hydroxylase	1	and	2	or	cytochrome	P450	11B1	and	2	CYP17A1	 steroid	17α-hydroxylase	1		or	steroid	17α-monooxygenase	or	cytochrome	P450	17a	1	CYP21A1	 steroid	21-hydroxylase		or	steroid	21-monooxygenase	or	cytochrome	P450	21a	1	GDM	 gestational	diabetes	mellitus	GLUT1,	GLUT3	 glucose	transporter	1,	glucose	transporter	3	H2-K	 H-2	class	I	histocompatibility	antigen,	K	HFD	 high-fat	diet	HLA	 human	leukocyte	antigen	HPA	axis	 hypothalamic-pituitary-adrenal	axis	HSD11B1,	HSD11B2	 11β-hydroxysteroid	dehydrogenase	type	1	and	2	HSD3B1	-	HSD3B6	 3β-hydroxysteroid	dehydrogenase/Δ5-isomerase	type	1-6	i.p.	 intraperitoneal	IL-1β	 interleukin-1β	IL-1Ra	 interleukin-1	receptor	antagonist	IL-6	 interleukin-6	ILC3	 group	3	innate	lymphoid	cells	INF-γ	 interferon-γ	M2	 alternatively	activated	macrophage	NET	 neutrophil	extracellular	trap	NETosis	 neutrophil	extracellular	trap	formation	PBS	 phosphate	buffered	saline	qPCR	 quantitative	polymerase	chain	reaction	rcf	 relative	centrifugal	force	RNA	 ribonucleic	acid	s.c.	 subcutaneous	SEM	 standard	error	of	the	mean	SGLT1	 sodium-glucose	co-transporter	SRD5A1-	SRD5A3	 3-oxo-5α-steroid	4-dehydrogenase	1,	2	and	3		or	steroid-5α-reductase	1,	2	and	3	T2DM	 type	2	diabetes	mellitus	TNF-α	 tumor	necrosis	factor-α	uNK-cells	 uterine	natural	killer	cells	
		
Introduction	
	Gestational	 diabetes	 mellitus	 (GDM)	 is	 one	 of	 the	 most	 frequent	 pregnancy-accompanying	diseases.	Depending	on	the	population	studied	and	the	diagnostic	criteria	used,	it	complicates	3-15%	of	all	pregnancies	[1,	2].	In	older	women	(45	years	and	older)	the	prevalence	rises	to	26%	[2]	and	in	obese	women	even	to	39%	[3].	GDM	is	defined	as	 impairment	of	glucose	tolerance,	with	or	without	 fasting	hyperglycemia,	which	develops	during	pregnancy	[1].	In	most	cases,	the	glucose-tolerance	impairment	resolves	after	delivery.		GDM	represents	a	risk	for	the	pregnant	woman	and	for	the	child:		During	 pregnancy,	 all	 forms	 of	 diabetes,	 including	 GDM,	 are	 a	 risk	 factor	 for	preeclampsia	 [4,	 5].	 	 At	 and	 around	 delivery,	 the	 following	 complications	 can	occur:	GDM	in	the	mother	often	causes	the	child	to	be	large	for	gestational	age	or	macrosomic	(weight	at	birth	≥	the	90th	percentile,	for	Caucasians	≥	4000g),	which	increases	 the	 risk	 for	 birth	 complications	 like	 shoulder	 dystocia	 and	 the	requirement	 for	 instrumental	 deliveries	 (forceps,	 caesarean	 section)	 [5].	Furthermore,	it	causes	high	plasma	insulin	concentrations	in	the	child.	After	the	circulation	of	the	child	is	separated	from	the	mother,	this	may	result	in	a	drop	of	the	child’s	blood	glucose,	resulting	in	life	threatening	hypoglycemia	[5].	The	risks	for	 jaundice	 [5],	 polycythemia	 [6],	 hypocalcemia	 and	 hypomagnesemia	 [7]	 are	increased	likewise,	as	well	as	the	risk	for	respiratory	distress	syndrome	[8].	Depending	of	the	length	of	the	follow	up	and	the	ethnicity,	2.6-70%	of	the	women	who	had	GDM	later	develop	type	2	diabetes	mellitus	(T2DM),	with	the	highest	risk	within	5	years	after	delivery	 [9].	The	 risk	 for	GDM	 in	a	 following	pregnancy	 is	increased	as	well	[1].		For	the	child,	the	lifelong	risk	to	develop	obesity,	T2DM	and	GDM	is	increased	[10].	Recently,	 also	 childhood	 asthma	 [11],	 atopic	 dermatitis	 and	 early	 childhood	allergen	sensitization	have	been	associated	to	GDM	[12].		The	pathophysiology	of	GDM	is	incompletely	understood.	One	reason	for	this	is	probably	that	our	understanding	of	the	glucose	metabolism	and	the	special	state	of	the	immune	system	during	normal	pregnancy	is	limited.			
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Glucose	metabolism	during	pregnancy	Glucose	 is	 an	 important	nutrient	 for	 the	developing	 fetus	 [13].	Along	with	 free	fatty	 acids	 and	 amino	 acids,	 glucose	 is	 transferred	 to	 the	 fetus	 through	 the	placenta.	 Studies	 in	 sheep	 and	 humans	 suggest	 a	 facilitated	 passive	 transport	along	 a	 glucose	 gradient	 [14].	 The	 most	 important	 glucose	 transporter	 of	 the	placenta	 is	glucose	transporter	1	(GLUT1)	[15],	although	also	the	expression	of	other	glucose	transporters	has	been	found,	like	GLUT3	in	human	placenta	and	the	sodium/glucose	co-transporter	(SGLT2)	 in	a	human	placental	cell	 line	[16,	17].	GLUT1	is	present	 in	both	membranes	of	 the	syncytiotrophoblast,	 that	means	 in	both	the	maternal	and	the	fetal	side	of	the	placental	barrier.	The	number	of	these	channels	 and	 the	 size	 of	 the	 syncytiothrophoblast	 are	 considered	 to	 be	 rate	limiting	for	glucose	transfer	to	the	fetus	[15].	However,	the	placenta	doesn’t	pass	on	all	of	the	glucose.	It	is	known	from	humans	and	rodents,	that	the	placenta	can	produce	and	store	glycogen	[18,	19].	Additionally,	large	proportions	of	the	glucose	that	 enters	 the	 placenta	 (depending	 on	 the	 gestational	 age)	 are	 used	 by	 the	placenta	itself	[20].		The	requirement	of	a	glucose	gradient	from	mother	to	child,	in	addition	to	the	high	glucose	 need	of	 the	 fetus,	 necessitates	 an	 increase	 of	maternal	 hepatic	glucose	production	 [21,	 22]	 and	 a	 reduction	 of	 other	 glucose	 sinks	 in	 the	 body	 of	 the	mother.	 To	 achieve	 this,	 the	 maternal	 body	 in	 humans	 and	 rodents	 develops	insulin	resistance	in	the	insulin	target	tissues	liver,	adipose	tissue	and	muscle	[23-25].	In	the	third	trimester	of	human	pregnancy,	there	is	a	50%	decrease	in	insulin-stimulated	 glucose	 disposal	 [23].	 The	 metabolism	 of	 the	 mother	 changes	 to	 a	higher	consumption	of	fatty	acids	and	ketone	bodies	to	spare	the	carbohydrates	for	the	fetus	[26].	Accordingly,	the	concentrations	of	these	nutrients	along	with	cholesterol	and	triglycerides	are	elevated	in	the	circulation	of	the	mother	[27].		It	 is	still	a	matter	of	debate	how	the	 insulin	resistance	of	 the	mother	develops.	From	studies	in	humans	and	animals	it	is	known	that	the	placenta	produces	many	hormones,	 which	 are	 known	 to	 induce	 insulin	 resistance,	 namely	 cortisol,	progesterone,	placental	lactogen,	placental	growth	hormone	and	estrogen	(at	high	levels)	 [24,	 28].	 The	 cytokines	 IL-1β	 and	 tumor	 necrosis	 factor-α	 (TNF-α)	 and	several	adipokines	such	as	leptin,	resistin	(both	during	pregnancy	predominantly	produced	 by	 the	 placenta)	 [29]	 and	 reduced	 adiponectin	 [30]	 have	 also	 been	
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associated	with	pregnancy-induced	insulin	resistance.	As	mentioned	before,	the	plasma	fatty-acid	concentration	is	increased	during	pregnancy,	further	adding	to	direct	hormonal	effects	on	insulin	sensitivity	[13].	Another	metabolic	adaptation	during	pregnancy	is	a	2-2.5	and	3-6-fold	increase	of	insulin	 secretion	 in	 humans	 [31]	 and	 mice	 [25]	 respectively.	 It	 is	 needed	 to	maintain	 euglycemia	 in	 face	 of	 the	 insulin	 resistance.	 This	 increased	 insulin	secretion	might	partly	be	a	direct	consequence	of	the	insulin	resistance	and	high	blood	 glucose.	 However,	 high	 blood	 glucose	 cannot	 be	 the	 only	 stimulus	 for	increased	insulin	secretion	during	pregnancy,	since	the	glucose	gets	transferred	to	the	fetus	[21,	25].	The	increased	insulin	secretion	is	achieved	by	an	increase	in	β-cell	mass	by	hypertrophy	and	hyperplasia,	and	a	higher	insulin	output	per	cell	[32].	 Many	 mechanisms	 are	 involved	 in	 the	 pregnancy-induced	 β	 cell-mass	expansion.	 For	 example,	 there	 are	 direct	 proliferation-inducing	 effects	 of	hormones	also	implicated	in	the	induction	of	the	insulin	resistance,	like	placental	growth	 hormone	 and	 lactogen,	 glucocorticoids	 and	 progesterone.	 Adiponectin	deficiency	led	to	reduced	β-cell	mass	in	mice	[33-36].	Further,	β	cells	need	to	down	regulate	 the	 expression	 of	 menin	 in	 order	 to	 be	 able	 to	 proliferate	 during	pregnancy	[37]	Most	studies	about	β	cell-mass	expansion	were	conducted	in	rodents.	Therefore,	it	is	important	to	note	that	there	might	be	differences	in	the	regulation	of	β-cell	expansion	in	humans	and	rodents.	One	study	showed,	that	in	contrast	to	rodents,	β-cell	 expansion	 during	 human	 pregnancy	 is	 primarily	 achieved	 through	 the	formation	 of	 new	 pancreatic	 islets	 arising	 from	 islet-cell	 progenitors	 such	 as	ductal	cells,	instead	of	proliferation	of	existing	β	cells	[38,	39].			
Immunological	changes	during	pregnancy	The	fetus	and	the	placenta	are	a	semi-allograft	 in	 the	body	of	 the	mother.	This	means	 that	 the	 fetal-placental	unit	has	 to	avoid	 rejection	 [40].	To	maintain	 the	pregnancy	 with	 simultaneous	 maintenance	 of	 immunological	 protection,	 the	systemic	innate	and	adaptive	immune	systems	of	the	mother	have	to	adapt.	The	lymphocyte	populations	are	decreased,	but	the	monocyte	and	neutrophil	counts	are	increased,	resulting	in	higher	total	leukocyte	counts	[41,	42].		
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Additionally,	 there	 is	 a	 highly	 specialized	 immune	 environment	 created	 at	 the	fetal-maternal	interface:		Placentas	 of	 primates	 and	 rodents	 are	 hemochorial,	 which	 means	 that	 fetal	trophoblast	 cells	 (cells	of	 the	placenta)	are	 in	 direct	 contact	with	 the	maternal	blood.	In	both,	primates	and	rodents,	trophoblast	cells	also	invade	the	uterine	wall	and	the	uterine	blood	vessels	at	the	implantation	site	of	the	placenta,	the	decidua	[43].	Except	 for	human	 leukocyte	antigen-C	(HLA-C)	 in	humans	and	H-2	class	 I	histocompatibility	 antigen,	 K	 (H2-K)	 in	 mice,	 the	 invading	 cells	 don’t	 express	classical	 major	 histocompatibility	 complex	 (MHC)	 class	 I	 molecules	 and	 are	therefore	barely	antigenic.	Human	invading	trophoblast	cells	express	HLA-G	and	HLA-E	 instead.	The	not	 invading	villous	trophoblast	cells	completely	 lack	MHC-complex	expression	in	humans	[44,	45].		Many	 specialized	 immune	 cells	 are	 located	 in	 the	 decidua.	 Their	 composition	changes	 with	 the	 progress	 of	 the	 pregnancy,	 and	 their	 function	 is	 not	 fully	understood.		During	the	first	trimester,	uterine	natural	killer	cells	(uNK-cells)	are	with	70-80%	of	total	immune	cells	the	most	abundant	immune	cell	types	of	the	decidua	in	mice	and	human	[46].	They	have	important	roles	in	the	decidualization,	the	trophoblast	invasion	 and	 the	 remodeling	 of	 the	 spiral	 arteries.	 Their	 cytotoxic	 function	 is	inhibited,	but	they	are	part	of	the	complex	immune-modulating	cytokine	network	and	express	IL-1β,	TNF-α,	interleukin-6	(IL-6)	and	interferon-γ	(IFN-γ)	and	other	cytokines	[47].	In	the	middle	of	the	pregnancy,	the	number	of	uNK-cells	starts	to	decline	and	reverts	back	to	pre-pregnancy	levels	in	the	third	trimester.		In	the	third	trimester	of	pregnancy,	myeloid	cells	are	the	most	abundant	immune	cells	in	the	decidua	of	mice,	including	neutrophils,	monocytes,	dendritic	cells	and	macrophages	[48].		Like	the	uNK-cells,	the	decidual	macrophages	decrease	in	number	towards	the	end	of	 pregnancy.	 Nevertheless,	 they	 are	with	 20-30%	 abundant	 decidual	 immune	cells	 throughout	 pregnancy	 [49].	 Several	 macrophage	 subpopulations	 with	distinct	functions	have	been	identified	in	the	decidua.	The	largest	subset	has	an	M2-like	phenotype,	responsible	for	phagocytosis	and	the	removal	of	cell	debris,	but	also	the	presence	of	a	more	proinflammatory	subset	has	been	reported	[50].			
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Dendritic	cells	in	the	decidua	are	of	myeloid	origin.	They	are	relatively	rare	but	important,	 inducing	 T-regulatory	 cells,	 recruiting	 NK-cells	 and	 regulating	angiogenesis.	Ablation	of	decidual	dendritic	cells	in	mice	led	to	increased	abortion	rates	[44].		Another	study	done	in	mice	showed	that,	in	contrast	to	other	dendritic	cells,	decidual	dendritic	cells	are	entrapped	in	the	decidua,	are	not	able	to	present	antigens	in	lymph	nodes	and	do	not	activate	T-cells	[51].	There	is	not	much	known	about	the	role	of	neutrophils	in	the	decidua,	although	they	 are	 an	 abundant	 resident	 cell	 type,	 especially	 in	 the	 second	 trimester.	Decidual	neutrophils	are	characterized	by	high	levels	of	activation	markers	and	the	expression	of	proteins	related	to	angiogenesis	in	both,	mice	and	humans	[52].	Recently,	 it	has	been	 shown	 that	group	3	 innate	 lymphoid	 cells	 (ILC-3)	 recruit	neutrophils	to	the	decidua	[53].				
Steroid	hormones	and	insulin	resistance	Placental	 steroid	hormones	 contribute	 to	pregnancy-induced	 insulin	 resistance	[28].	However,	the	insulin-desensitizing	effect	of	glucocorticoids	and	sex	steroids	are	 not	 restricted	 to	 pregnancy.	 Progesterone	 and	 estradiol	 influence	 insulin	sensitivity	 of	 women	 during	 the	menstrual	 cycle	 [54].	Women	with	 polycystic	ovary	 syndrome	 (a	 state	of	hyperandrogenemia)	 suffer	 from	 insulin	 resistance	[55].	 In	 contrast	 to	 this,	 the	 sex	hormones	 testosterone	and	estrogen	 (at	 lower	levels	than	during	pregnancy)	prevent	mice	from	becoming	insulin	resistant	[56,	57].	 Testosterone	 replacement	 therapy	 improved	 insulin	 sensitivity	 in	hypogonadal	men	with	T2DM	[58].		Patients	with	chronically	increased	cortisol	levels	(Cushing	syndrome)	suffer	from	insulin	 resistance	 [59].	 Together	 with	 catecholamines	 and	 cytokines,	glucocorticoids	reduce	 insulin	sensitivity	 in	obesity	and	psychiatric	stress	[60].	Corticosterone,	the	most	important	glucocorticoid	in	rodents	[61],	induces	insulin	resistance	in	mice	[62].	Male	leptin-resistant,	highly	insulin	resistant	db/db	mice	have	 increased	 plasma	 levels	 of	 aldosterone,	 corticosterone,	 11-deoxycorticosterone	and	progesterone,	along	with	increased	gene	expression	of	the	enzymes	involved	in	the	synthesis	of	these	steroid	hormones	in	the	adipose	tissue	[63].	
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Interestingly,	IL-1β	has	been	shown	to	stimulate	the	production	of	various	steroid	hormones:	It	stimulates	the	production	of	progesterone	from	a	human	placental	cell	line	[64]	and	bovine	granulosa	cells	(cells	in	ovarian	follicles)	[65].	In	rodents,	IL-1β	 stimulates	 the	 increase	 of	 serum	 corticosterone	 by	 influencing	 the	hypothalamic-pituitary-adrenal	 axis	 (HPA	 axis)	 on	 hypothalamic,	 pituitary	 and	adrenal	level	[66-69].	In	humans,	the	administration	of	IL-1Ra	decreases	serum	cortisol	in	obese	individuals	[70].		
Pathophysiology	of	gestational	diabetes	In	GDM,	many	parts	of	the	metabolic	and	immunological	adaptation	to	pregnancy	do	not	work	properly.	Metabolically,	GDM	is	characterized	by	a	further	increase	of	insulin	 resistance	with	an	 inadequate	 insulin	 response	by	 the	pancreatic	 islets.	Although	the	islets	of	women	with	GDM	secrete	more	insulin	than	that	of	women	with	healthy	pregnancies,	it	is	not	enough	to	overcome	the	insulin	resistance	[31,	71].	 It	 is	not	known	 if	β-cell	mass	 is	 altered	 in	women	with	GDM	compared	 to	women	 with	 healthy	 pregnancies,	 but	 mouse	 models,	 in	 which	 the	 β-cell	proliferation	was	hampered,	led	to	GDM	[33,	36,	37,	72].	At	 a	 cellular	 level,	GDM	 is	 associated	with	 impaired	 insulin	signaling	 in	muscle	cells,	hepatocytes	and	adipocytes.	This	results	in	a	65%	reduced	glucose	disposal	compared	 to	 non-pregnant	 women,	 increased	 lipolysis	 and	 increased	 hepatic	glucose	production	[21,	73].	The	release	of	leptin	from	the	placenta	is	decreased	in	GDM,	but	the	release	from	adipose	tissue	is	increased	compared	to	healthy	pregnant	women	[29].	One	of	 the	most	 important	 risk	 factors	 for	GDM	 is	obesity.	Obese	women	have	more	 inflammatory	macrophages	 accumulating	 in	 the	 placenta,	which	 produce	cytokines	like	IL-1,	TNF-α	and	IL-6,	compared	to	lean	pregnant	women	[74].	TNF-α,	IL-6	and	C-reactive	protein	(CRP)	are	increased	in	the	circulation	of	women	with	GDM,	as	well	as	and	the	expression	of	TNF-α	and	IL-6	in	the	adipose	tissue	[75].	Among	 various	 other	 effects,	 the	 increased	 TNF-α	 in	 the	 circulation	 leads	 to	increased	 formation	 of	 neutrophil	 extracellular	 traps	 (NETosis)	 of	 peripheral	neutrophils	in	women	with	GDM	[76].			
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IL-1β	is	also	increased	in	the	serum	of	women	with	GDM,	and	in	obese	pregnant	women	[77,	78].	In	the	adipose	tissue	of	women	with	GDM,	the	inflammasomes	are	 induced	 [79],	 presumably	 by	 high	 concentrations	 of	 free	 fatty	 acids	 and	increased	endoplasmatic	reticulum	stress	[80],	leading	to	IL-1β	secretion.	Obesity	and	GDM	are	associated	with	decreased	circulating	adiponectin	[30,	77].	Adiponectin-deficient	 mice	 develop	 GDM	 with	 increased	 insulin	 resistance,	increased	hepatic	glucose	production	and	decreased	β-cell	mass	during	pregnancy	[36].		Until	 recently	 the	 placenta	 and	 decidua	 were	 thought	 to	 be	 sterile.	 This	 view	changed	with	the	discovery	of	a	placental	microbiome,	which	is	distinct	from	other	microbiota	of	the	human	body	[81].	In	the	meantime,	it	has	been	shown	that	GDM	and	excessive	weight	gain	during	pregnancy	are	accompanied	by	changes	in	this	microbiome	[82,	83].	Further,	the	gut	microbiome	is	also	altered	in	women	with	GDM	[84].			
IL-1β	and	type	2	diabetes	IL-1β	was	the	first	cytokine	to	be	discovered.	In	the	1970s,	it	has	been	described	as	the	factor	causing	fever	and	as	a	mitogen	for	T-cells	[85,	86].	Today,	it	is	known	as	a	master	regulator	of	inflammation	with	multiple	functions	in	physiology	and	pathophysiology	[87,	88].		In	the	last	20	years,	it	has	become	evident	that	obesity-induced	insulin	resistance	is	 mediated	 through	 inflammatory	 factors,	 including	 IL-1β	 [89,	 90].	 In	 obese	subjects	 and	 patients	 with	 T2DM,	 IL-1β	 secretion,	 presumably	 from	 tissue	resident	macrophages	[91],	is	increased	in	insulin-sensitive	tissues.		Furthermore,	it	has	been	shown	that	IL-1β	is	upregulated	in	pancreatic	islets	of	patients	 with	 T2DM	 and	 that	 IL-1β	 contributes	 to	 β-cell	 glucotoxicity	 and	lipotoxicity,	to	β-cell	destruction	and	dedifferentiation	[92-96].		Since	IL-1β	causes	insulin	resistance	and	β-cell	failure,	and	has	furthermore	a	role	in	the	cardiovascular	complications	of	diabetes	[97]	it	is	an	attractive	therapeutic	target	[98].	In	a	clinical	study,	IL-1	antagonism	using	the	IL-1	receptor	antagonist	(IL-1Ra)	improved	gylcemia	and	insulin	secretion	in	patients	with	T2DM	[99].				
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Currently,	 the	 CANTOS	 trial,	 a	 phase	 III	 clinical	 study	 with	 more	 than	 10000	participants,	 investigates	 if	 Canakinumab,	 a	 neutralizing	monoclonal	 anti-IL-1β	antibody	is	effective	in	reducing	the	incidence	and	influencing	the	course	of	T2DM	[100].		
	
Aim	of	this	study	Since	IL-1β	is	increased	in	women	with	GDM	and	has	a	role	in	T2DM,	and	since	IL-1β	antagonism	improves	β-cell	function	and	insulin	sensitivity	in	diabetic	subjects	[99,	101]	we	aim	to	study	the	effect	of	IL-1β	antagonism	on	glucose	metabolism	during	pregnancy	of	normal	mice	and	in	a	mouse	model	of	GDM.				 	
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Materials	and	Methods		
Mice:	All	mouse	experiments	were	approved	by	the	animal-welfare	committee	of	 the	Kanton	 Basel	 Stadt.	 Mice	 were	 either	 purchased	 from	 Charles	 River	 (Sulzfeld,	Germany)	or	originated	 from	our	 in-house	breeding.	For	 the	experiments	with	wild-type	mice	we	used	C57BL/6N	mice,	all	transgenic	mice	were	on	a	C57BL/6N	background.	 All	 experiments	 with	 transgenic	 mice	 were	 done	 with	 littermate	controls.		We	used	two	transgenic	mouse	models.	A	constitutive,	whole-body	IL-1β-deficient	mouse	strain	(IL-1β	KO)	and	a	myeloid	lineage-specific	IL-1β-deficient	mouse:	the	
Il1bfl/flLyz2-Cre	mouse	(LysMCre-IL-1β	KO)	[88].	The	work	with	the	LysMCre-IL-1β	KO	mouse	was	performed	together	with	Valmir	Makshana.	Female	mice	of	different	ages	were	timed-mated.	Used	bedding	of	cages	of	males	was	put	 into	the	cages	of	 the	 females	to	align	their	menstrual	cycle	and	 induce	their	 estrus.	2.5	days	 later,	 the	 females	were	 transferred	 into	 the	 cage	of	male	breeders	for	24h,	before	returning	to	their	own	cage.	The	day	of	plug	detection	was	regarded	as	day	0.5	of	pregnancy.		If	indicated,	mice	received	one	single	i.p.	injection	of	a	murine	anti-IL-1β	antibody	(BSUR05,	with	the	same	specificity	as	canakinumab;	kindly	provided	by	Novartis,	Switzerland),	or	vehicle	on	day	7.5	of	pregnancy.	Metabolic	 testing	of	 the	mice	followed	on	day	13.5	of	pregnancy	and	the	sacrifice	on	day	14.5	of	pregnancy.	If	indicated,	mice	received	a	high-fat	diet	with	60	kJ%	fat	(lard;	ssniff	Spezialitäten,	Soest,	 Germany),	 all	 other	 mice	 received	 normal	 mouse	 chow	 diet	 (Kliba,	Kaiseraugst,	Switzerland).	If	not	indicated	differently,	all	mice	had	free	access	to	food	and	water	and	were	housed	in	a	12-hours	light	and	dark	cycle	with	the	light	phase	during	the	day.		All	 experiments	were	 repeated	with	 at	 least	 three	 independent	 cohorts,	 if	 not	indicated	otherwise.		
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Metabolic	testing:	Glucose	tolerance	testing:	For	glucose	tolerance	tests,	mice	were	fasted	for	6	hours	in	 the	morning.	The	 fasted	mice	received	a	subcutaneous	bolus	 injection	of	2	g	glucose	per	kg	body	weight.	Blood	glucose	was	measured	prior	to,	and	15,	30,	60,	90	and	120	minutes	after	the	injection,	each	with	a	drop	of	capillary	blood	from	the	tail	tip,	using	FreeStyle	Lite	glucose	meters	(Abbott	AG,	Baar,	Switzerland).	At	the	first	three	time	points,	additional	blood	samples	were	taken	from	the	tail	tip	into	tubes	containing	EDTA	to	measure	plasma	insulin	with	the	MSD	Mouse/Rat	Insulin	Kit	(Mesoscale	Discovery,	Rockville	MD,	USA)	according	to	the	instructions	of	the	manufacturer.	The	insulinogenic	index	was	calculated	as	follows:		𝑖𝑛𝑠𝑢𝑙𝑖𝑛𝑜𝑔𝑒𝑛𝑖𝑐	𝑖𝑛𝑑𝑒𝑥 = (𝑝𝑙𝑎𝑠𝑚𝑎	𝑖𝑛𝑠𝑢𝑙𝑖𝑛	154 − 𝑏𝑎𝑠𝑎𝑙	𝑝𝑙𝑎𝑠𝑚𝑎	𝑖𝑛𝑠𝑢𝑙𝑖𝑛)(𝑏𝑙𝑜𝑜𝑑	𝑔𝑙𝑢𝑐𝑜𝑠𝑒	154 − 𝑏𝑎𝑠𝑎𝑙	𝑝𝑙𝑎𝑠𝑚𝑎	𝑖𝑛𝑠𝑢𝑙𝑖𝑛) 	Insulin	tolerance	testing:	Mice	were	 fasted	 for	 three	hours	 in	 the	morning.	The	fasted	mice	received	a	subcutaneous	injection	of	0.01	IU	insulin	(Actrapid,	Novo	Nordisk,	Copenhagen,	Denmark)	and	blood	glucose	was	measured	as	described	for	the	glucose	tolerance	testing.				
Serum	preparation:		Serum	was	 obtained	 by	 allowing	 fresh	 blood	 to	 stand	 for	 30	minutes	 at	 room	temperature,	followed	by	centrifugation	at	2000	rcf	for	20	minutes.		
Serum	IL-1β	measurements:		Serum-IL-1β	 measurements	 were	 performed	 with	 the	 MSD	 mouse	 IL-1β	 Kit	(Mesoscale	 Discovery)	 according	 to	 the	 “alternative	 protocol	 2”	 of	 the	manufacturer’s	instructions.			
Serum	hormone	measurements:	Serum	 steroid	 hormones	 were	 quantified	 using	 ultra	 performance	 liquid	chromatography	 -	 tandem	 mass	 spectrometer	 (UPLC-MS/MS)	 as	 described	 in	[102].	The	measurements	were	performed	by	Denise	Kratschmar,	University	of	Basel,	Department	of	Pharmaceutical	Sciences,	Klingelbergstrasse	50,	4056	Basel.	
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Ribonucleic	acid	(RNA)	extraction	and	quantitative	polymerase	chain	
reaction	(qPCR):	Islets	and	whole-blood	cells	were	directly	lysed,	tissue	was	homogenized	with	an	electrical	Polytron	homogenizer	(Kinematica,	Lucerne,	Switzerland)	in	lysis	buffer	of	 the	 RNA	 extraction	 kit.	 RNA	 was	 isolated	 using	 the	 NucleoSpin	 RNA	 II	 Kit	(Macherey	 Nagel,	 Düren,	 Germany)	 according	 to	 the	 instructions	 of	 the	manufacturer.	Complementary	deoxyribonucleic	acid	(cDNA)	was	prepared	using	the	deoyxnucleoside	 triphosphate	 (dNTP)	 set	 (Roche	Diagnostics,	 Indianapolis,	IN,	USA),	1OD	260	hexamer	(Mircrosynth,	Balgach	Switzerland)	and	SuperScript	II	reverse	transcriptase	(Invitrogen,	Carlsbad,	CA,	USA)	and	used	for	qPCR.	For	qPCR	 we	 used	 GoTaq	 polymerase	 mixes	 (GoTaq	 Probe	 qPCR	 Master	 mix	 for	Taqman	 probes	 and	 GoTaq	 qPCR	Mastermix	 for	 the	 SYBRgreen	method;	 both	Promega,	 Catalys,	 Switzerland)	 and	 the	 following	 ABI	 Taqman	 probes	(ThermofisherScientific,	 Reinach,	 Switzerland):	 Il1b:	 Mm00434228,	 Gapdh:	Mm99999915,	Actinb:	Mm00607939,	18s:	Hs99999901_s1,	Mki67:	Mm01278617,	
Ccna2:	Mm00438063,	Pcna:	Mm00448100_g1.	The	primers	(Microsynth)	used	for	SYBR	green	detection	are	listed	in	table	1.		
Table	1:	
target	 direction	 primer	
Gapdh	 forward	 AGGTCGGTGTGAACGGATTTG	reverse	 TGTAGACCATGTAGTTGAGGTCA	
Actinb	 forward	 GGCTGTATTCCCCTCCATCG	reverse	 CCAGTTGGTAACAATGCCATGT	
Cyp11b1	 forward	 AGAGCTGGTAGCTGAGAGAAC	reverse	 CCTTCTGAGGATTTGCAGCGA	
Cyp11b2	 forward	 CGTGGCCTGAGACGTGGTGT	reverse	 CATCCATGGTAAGGCTCCCACGA	
Cyp21a1	 forward	 TCCCCTTTCTCAGGTTCCTCC	reverse	 CTTTCCATTGGCCTGCAACC	
 
Mouse	islet	isolation:	Islets	were	isolated	using	collagenase	digestion	(4189,	Worthington,	Lakewood,	NJ,	USA).	The	pancreas	was	perfused	with	collagenase	solution	in	situ,	dissected	and	incubated	for	28	min	at	37°C	in	a	water	bath.		Subsequently,	the	islets	were	washed,	filtered	with	a	70µm	cell	strainer	(Corning,	Durham,	NC,	USA)	and	hand-picked	[103].			
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β-Cell	area	determination:	Mouse	pancreata	were	dissected	and	fixed	in	4%	formalin	(Hittnau,	Switzerland)	over	night,	washed	in	phosphate	buffered	saline	(PBS)	and	embedded	in	paraffin.	Of	 each	pancreas,	 serial	 sections	of	5	µm	were	 taken	every	100	µm	 trough	 the	pancreas.	This	resulted	in	6-13	sections	per	pancreas.	The	sections	were	stained	after	 heat-induced	 antigen	 retrieval	 in	 Target	 Retrieval	 Solution	 (pH=6,	 Dako,	Aligent	Technologies,	Santa	Clara,	CA,	USA).	The	following	antibodies	were	used	for	staining:	primary:	polyclonal	guinea	pig-anti-insulin	(Dako;	1:200);	secondary:	Fluorescein	(FITC)-conjugated	donkey	anti-guinea	pig	(Jackson	ImmunoResearch,	1:200).	Nuclei	were	stained	with	DAPI,	dilactate	(Sigma,	1:100000)	added	to	the	secondary	antibody.		Insulin	was	stained	to	determine	the	area	of	β	cells	on	each	section.	The	DAPI-signal	was	used	to	determine	the	total	pancreatic	area	of	the	section.	β-cell	area	is	presented	as	insulin-positive	area	divided	by	the	total	pancreas	area.	Microscopy	was	 performed	 with	 an	 Olympus	 IX83	 microscope.	 For	 picture	 analysis,	 the	CellSence	software	(Olympus	Schweiz	AG,	Volketswil,	Switzerland)	was	used.		
Graphs	and	statistics	For	graphs	and	statistics	we	used	Prism	7	software	(Graph	Pad,	La	Jolla,	CA,	USA).	Outliers,	identified	with	the	ROUT	test,	were	excluded	with	a	sample	size	of	above	5.	 The	 statistical	 test	 used	 in	 each	 study	 is	 noted	 in	 the	 corresponding	 figure	legend.		
		
Results	
A	mouse	model	of	gestational	diabetes	We	tested	if	GDM	can	be	induced	in	C57BL/6N	mice	by	applying	two	important	risk	factors	for	GDM:	age	and	obesity.	Therefore,	mice	were	mated	at	different	ages	and	fed	either	normal	chow	or	a	high-fat	diet.	Mice,	which	didn’t	become	pregnant,	served	as	controls.	We	measured	fasting	glucose	and	glucose	tolerance	on	day	13.5	of	 pregnancy,	 which	 is	 at	 the	 beginning	 of	 the	 third	 trimester	 of	 a	 mouse	pregnancy.	 The	 glucose	 tolerance	 was	 tested	 using	 subcutaneous	 glucose	tolerance	tests,	in	which	the	mice	received	a	subcutaneous	glucose-bolus	injection	after	a	 fasting	period	of	6	hours.	The	 insulinogenic	 index	 is	 the	quotient	of	 the	insulin	increment	(Δ	insulin)	and	the	glucose	increment	(Δ	glucose)	15	minutes	after	the	glucose	bolus	injection.			Pregnant	young	(10-13	weeks	old)	chow-fed	mice	had	mildly	 impaired	glucose	tolerance	 with	 mildly	 increased	 fasting	 glucose	 compared	 to	 non-pregnant	controls.	Their	plasma	insulin	was	increased	basally	and	throughout	the	test.	The	insulinogenic	index	in	pregnant	and	control	mice	was	not	significantly	different	(Fig.	1A,	E,	I,	M).		Older	(15-18	weeks	old)	chow-fed	mice	had	a	similar	glucose	phenotype	(Fig.	1B,	F,	J,	N).	These	models	will	further	be	referred	to	as	“healthy	pregnant”.		To	test	if	high-fat	diet	feeding	during	pregnancy	would	be	sufficient	to	cause	GDM,	chow-fed	mice	were	 switched	 to	 high-fat-diet	 feeding	 after	 timed	mating.	 The	controls	received	high-fat	diet	during	this	time,	as	well.	This	resulted	in	two	weeks	of	 high-fat-diet	 feeding	 before	 the	 metabolic	 testing	 at	 16	 weeks	 of	 age.	 The	glucose	tolerance	of	both,	pregnant	and	control	mice,	was	impaired	compared	to	that	of	mice	of	the	same	age	fed	chow	diet,	along	with	increased	plasma	insulin	levels.	The	 impairment	of	 glucose	 tolerance	and	 the	 increase	of	plasma	 insulin	were	 more	 pronounced	 in	 the	 pregnant	 mice,	 both	 blood	 glucose	 and	 plasma	insulin	 were	 increased	 compared	 to	 the	 controls.	 Fasting	 blood	 glucose	 and	insulinogenic	index	were	similar	and	comparable	to	that	of	the	
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Figure 1
Glucose tolerance (A-D), plasma insulin (E-H), fasting blood glucose (I-L) and insulinogenic index (M-P) 
of pregnant mice on day 13.5 of pregnancy: A, E, I, M: 10-13 weeks old mice fed normal chow diet: 
control n=16, pregnant n=7; B, F, J, N: 15-18 weeks old mice fed normal chow: control n=44, pregnant 
n=24; C, G, K, O: 16 weeks old mice fed chow before pregnancy, but HFD during pregnancy: control 
n=20, pregnant n=13; D, H, L, P: 19-21 weeks old mice fed HFD for 3-6 weeks before mating and 
during pregnancy, control n=22, pregnant n=9; all data as mean ± SEM, statistics in A-H: 2way ANOVA 
for repeated measurements with Holm-Sidak multiple comparisons, statistics in I-P: Mann-Whitney test. 
Figure 1
		
chow-fed	healthy	pregnant	mice	(Fig.	1C,	G,	K,	O).	This	model	will	be	referred	to	as	“short-term	high	fat	diet”.		Ultimately,	mice	were	fed	high-fat	diet	3-6	weeks	before	timed	mating	at	the	age	of	17-18	weeks	and	throughout	pregnancy,	resulting	in	5-8	weeks	of	high-fat-diet	feeding	 on	 the	 day	 of	 the	 glucose	 tolerance	 tests	 at	 the	 age	 of	 19-21	 weeks.	Controls	 received	 the	 same	 diet.	 In	 these	 tests,	 pregnant	 mice	 had	 a	 marked	impairment	 of	 glucose	 tolerance	 compared	 to	 the	 controls.	 The	 controls	 also	showed	 an	 impairment	 of	 glucose	 tolerance	 compared	 to	 the	 controls	 in	 the	healthy	 pregnant	 and	 short-term	high-fat	 diet	 groups.	 The	 insulin	 secretion	 of	pregnant	mice	 and	 controls	was	 similar.	 Nevertheless,	 the	 insulinogenic	 index	showed	no	difference.	The	 fasting	glucose	was	 the	 same	 (Fig.	1D,	H,	L,	P).	This	model	will	further	be	referred	to	as	“GDM	model”.		Taking	into	account	all	pregnant	mice	from	all	models	described	above,	the	area	under	the	curve	(AUC)	of	the	glucose	tolerance	tests	of	pregnant	mice	positively	correlated	with	the	weight	of	the	mice	before	pregnancy	(Fig.	2A).		Mice	 fed	a	high-fat	diet	 tended	to	be	more	 fertile	 then	mice	 fed	chow	diet.	The	percentage	 of	 pregnant	 mice	 after	 timed-mating	 was	 higher	 in	 females	 that	received	high-fat	diet.	This	difference	was	statistically	not	significant	(Fig.	2B).		
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	A	 known	 risk	 of	 GDM	 in	 humans	 is	 macrosomia	 of	 the	 child.	 Therefore,	 we	measured	the	fetal	weight	of	healthy	pregnant	mice,	short-term	high-fat	diet	mice	and	GDM	mice	at	sacrifice	(Fig.	3).	Older	healthy	pregnant	mice	had	on	average	smaller	 fetuses	than	younger	healthy	pregnant	mice,	whereas	the	average	 fetal	weight	of	short-term	high-fat	diet	mice	and	GDM	mice	was	not	different	(Fig.	3A).	The	 total	 fetal	weight	 (the	 sum	of	 the	weight	of	 all	 fetuses	 from	one	 pregnant	mouse;	Fig.	3B)	and	the	litter	size	(the	number	of	pubs	per	pregnant	mouse;	Fig.	3C)	 were	 not	 dependent	 on	 age	 or	 diet	 of	 the	 pregnant	 mouse.
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A: Area under the curve of the glucose tolerance tests and the body weight before pregnancy 
of all pregnant mice from figure 1 n=49, with linear regression; B: Fertility expressed as % of 
mice which became pregnant at timed-mating: HFD: n=11, chow: n=66 
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		To	examine	if	GDM	mice	have	increased	IL-1β	levels,	we	measured	IL-1β	in	the	serum	of	our	mouse	models	under	two	conditions:	In	6-hours	fasted	mice	in	the	afternoon	(at	2	p.m.;	Fig.	4A	and	C)	and	in	not	fasted	mice	in	the	afternoon	(at	3	p.m.;	Fig.	4B	and	D).	The	serum	IL-1β	did	not	differ	in	fasted	mice,	although	the	serum	 IL-1β	 of	 mice	 in	 the	 GDM	 model	 was	 higher	 than	 that	 in	 the	 healthy	pregnant	model	(Fig.	4A	and	B).		However,	 not	 fasted	 pregnant	 mice	 had	 higher	 serum	 IL-1β	 levels	 than	 the	controls,	both	in	the	healthy	pregnant	model	and	in	the	short-term	high-fat	diet	model	(Fig.	4C	and	D).	Unfortunately,	the	sample	size	in	the	not	fasted	condition	was	 small	 and	 we	 have	 no	 sera	 from	 not	 fasted	 GDM	 mice.
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A-C: Average fetal weight, tolal litter weight and litter size, respectively, in all pregnant mice from 
figure 1, healthy 10-13 weeks n=9, healthy 15-18 weeks n=18, short-term HFD n=9, GDM n=18; 
data as mean ± SEM, statistics: Kruskal-Wallis test with Dunn’s multiple comparison.  
Figure 3: Fetal Weight
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Organ/tissue	Il1b	gene	expression	in	pregnant	mice	By	measuring	the	Il1b	gene	expression	in	candidate	organs	and	tissues,	we	tried	to	localize	the	source	of	increased	IL-1β	in	pregnant	mice	that	might	influence	the	glucose	tolerance	(Fig.	5).	We	isolated	RNA	from	pieces	of	tissues,	from	peripheral	blood	cells	and	from	isolated	islets	and	tested	if	Il1b	gene	expression	was	altered	during	healthy	pregnancy	or	in	GDM.	All	samples	were	collected	on	day	14.5	of	pregnancy.	
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Figure 4
Serum IL-1β of A: Fasted healthy pregnant mice: control n=7, pregnant n=4; B: Not fasted healthy 
pregnant mice: control n=22,  pregnant n=12; C: Fasted GDM mice: control n=20, pregnant n=13; 
D: Not fasted short-term HFD mice: control n=5, pregnant n=4; data as mean ± SEM, statistics with 
Mann-Whitney test  
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Figure 5
IL1b gene expression in candidate organs/ tissues in pregant mice and not pregnant controls. A-E: IL1b gene expression in 
GDM mice A: Islets: control n=3, pregnant n=4; B: Subcutaneous fat: control n=12, pregnant n=12;  C: Liver: control n=10, 
pregnant n=5; D: Peripheral blood cells control n=5, pregnant n=3; E: Uterus controls n=6, pregnant n=14;
F-K: IL1b gene expression in healthy pregnant mice. F: Islets: control n=14, pregnant n=16; G: Muscle: control n=8, pregnant 
n=8; H: Subcutaneous fat: control n=7, pregnant n=7; I: Liver: control n=13, pregnant n=12; J: Peripheral blood cells: control 
n=9, pregnant n=7; K: Uterus: control n=4, pregnant n=5; data expressed as mean ± SEM; statistics: Man-Whitney test, note 
the different scales of the y-axes. 
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Figure 6
qPCR results expressed as ct-values for the reference genes Actinb (A), Gapdh (B) and 18s (C); 
healthy control: n=4, healthy pregnant: n=5, GDM control: n=15, pregnant GDM: n=6; data as mean 
± SEM
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Figure 6: Reference Gene Expression in Uterus
		
		There	was	no	difference	of	 Il1b	gene	expression	 in	 islets	and	the	subcutaneous	adipose	 tissue	 of	 pregnant	 mice	 of	 the	 GDM	model	 (Fig.	 5A,	 B),	 and	 in	 islets,	muscle,	 subcutaneous	 adipose	 tissue	 and	 peripheral	 blood	 cells	 of	 healthy	pregnant	mice	compared	to	non-pregnant	controls	(Fig.	5F,	G,	H,	J).	In	GDM	mice,	there	was	a	trend	for	lower	Il1b	expression	in	the	liver	(Fig	5C)	and	peripheral	blood	cells	(Fig.	5D).	In	healthy	pregnant	mice,	there	was	a	trend	for	lower	Il1b	gene	expression	in	the	liver	as	well	(Fig	5I).		
Il1b	expression	in	the	uterus	of	pregnant	mice	was	increased	in	GDM	mice	(Fig.	5E)	and	tended	to	be	 increased	 in	healthy	pregnancy	(Fig.	5K).	To	extract	RNA	from	the	uterus,	we	only	took	the	uterus	wall	with	the	decidua.	We	dissected	off	the	placenta	(the	RNA	of	the	placenta	was	analyzed	separately),	fetus	and	amnion.	In	the	uterus,	not	only	the	expression	of	Il1b	was	increased,	but	also	the	expression	of	 the	 reference	 genes	 Actinb	 and	 Gapdh,	 despite	 the	 same	 RNA	 input	 to	 the	reverse	transcription	(Fig.	6A	and	B).	Thus,	data	for	this	organ	were	normalized	to	the	expression	of	18s,	which	was	more	stable	than	Actinb	and	Gapdh	(Fig.	6C).			
Inhibition	of	IL-1β	in	GDM	mice	and	healthy	pregnant	mice	Hypothesizing	 that	 IL-1β	 contributes	 to	 the	 impaired	 glucose	 tolerance	 of	pregnant	mice	with	GDM,	we	inhibited	IL-1β	using	a	murine	neutralizing	anti-IL-1β	antibody	(anti-IL-1β)	with	the	same	specificity	as	canakinumab.	Anti-IL-1β	was	administered	as	single	dose	with	an	i.p.	injection	on	day	7.5	of	pregnancy,	which	is	at	the	beginning	of	the	second	trimester.		Anti-IL-1β	treatment	improved	the	glucose	tolerance	of	pregnant	GDM	mice	(Fig.	7A).	 Although	 not	 significant,	 there	 was	 a	 trend	 for	 higher	 glucose-stimulated	insulin	secretion	in	pregnant	GDM	mice	treated	with	anti-IL-1β	(Fig.	7B),	but	not	in	the	non-pregnant	control	mice.	Nevertheless,	the	insulinogenic	index	tended	to	be	improved	in	both	pregnant	and	non-pregnant	mice	(Fig.	7D).	The	fasting	blood	glucose	was	not	affected	by	anti-IL-1β	(Fig.	7C).	
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Figure 7
GDM Model
D
Figure 7
A-D: GDM model with 19-21 weeks old,pregnant and not pregnant mice with or without anti-IL-1β 
treatment,  fed HFD for 3-6 weeks before mating and during pregnancy: A: Glucose tolerance, B: 
Corresponding insulin, C: Blood glucose in fasted mice, D: Insulinogenic index;  control n=22, anti-
IL-1β: n=21, pregnant n=9, pregnant anti-IL1β: n=7; all data as mean ± SEM, statistics in A and B: 
2way ANOVA for repeated measurements with Holm-Sidak multiple comparisons; *= control vs. 
pregnant, += pregnant vs. anti-IL-1β pregnant.
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Healthy Pregnancy Model
D
Figure 8
A-D: Healthy pregnancy model with 15-18 weeks old, chow fed pregant and not pregnant mice 
treated anti-IL-1β or vehicle: A: Glucose tolerance, B: Corresponding insulin, C: Blood glucose in 
fasted mice, D: Insulinogenic index; control n=44, anti-IL-1β: n=37, pregnant n=24, pregnant anti-
IL1β: n=19; all data as mean ± SEM, statistics in A and B: 2way ANOVA for repeated 
measurements with Holm-Sidak multiple comparisons. *= control vs. pregnant, += pregnant vs. 
anti-IL-1β pregnant.
		
	To	test	if	the	anti-IL-1β-induced	improvement	of	the	glucose	tolerance	only	occurs	in	GDM	or	also	in	healthy	pregnancies,	we	antagonized	IL-1β	in	15-18	weeks	old	healthy	pregnant	mice.	There	was	a	very	small,	but	significant	improvement	of	the	glucose	tolerance	of	pregnant	mice	(Fig.	8A).	Plasma	insulin,	fasting	blood	glucose	and	insulinogenic	index	were	unaffected	by	anti-IL-1β	treatment	(Fig.	8B-D).			To	 support	 the	 results	 obtained	 with	 anti-IL-1β	 treatment	 in	 the	 healthy	pregnancy	model,	 we	 performed	 glucose	 tolerance	 tests	 in	 constitutive,	 whole	body	IL-1β	knock	out	mice	(IL-1β	KO	mice)	and	their	littermate	controls	(Fig.	9).	The	mice	were	15-19	weeks	old	and	fed	a	chow	diet.		Pregnant	control	mice	had	a	mild	impairment	of	glucose	tolerance	(Fig.	9A)	and	their	 plasma	 insulin	 levels	 tended	 to	 be	 increased	 compared	 to	 non-pregnant	controls	(Fig.	9B).	The	insulinogenic	index	of	pregnant	wild	type	mice	tended	to	be	lower	than	that	of	non-pregnant	controls	(Fig.	9D).	The	 glucose	 tolerance	 of	 pregnant	 IL-1β	 KO	mice	 was	 less	 impaired,	 with	 no	significant	 difference	 compared	 to	 non-pregnant	 IL-1β	 KO	 mice	 or	 pregnant	control	mice.	 Interestingly,	 the	 plasma	 insulin	 of	 pregnant	 IL-1β	 KO	mice	was	increased	 compared	 to	 all	 other	 groups,	 basally	 as	 well	 as	 after	 the	 glucose	injection.	The	insulinogenic	index	of	pregnant	IL-1β	KO	mice	tended	to	be	better	than	that	of	pregnant	wild	type	mice,	and	that	of	non-pregnant	IL-1β	KO	mice.	The	fasting	blood	glucose	levels	of	all	groups	were	similar	(Fig.	9C).			
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β-Cell	area	and	islet	gene	expression	of	proliferation	markers	To	investigate	if	anti-IL-1β	has	an	influence	on	the	β-cell	mass	expansion	during	healthy	 pregnancy,	 we	 measured	 the	 β-cell	 area	 on	 6-13	 serial	 histological	sections	per	pancreas	of	mice	of	 the	healthy	pregnancy	model	(Fig.	10	and	11).	The	ratio	of	β-cell	area	and	total	pancreas	area	serves	as	a	surrogate	marker	for	the	β-cell	mass.		There	was	a	trend	for	increased	β-cell	area,	average	islet	size	and	number	of	islets	with	pregnancy,	where	the	increase	of	the	islet	number	is	the	most	
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Figure 9: IL-1β KO mice
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Figure 9:
A-D: Pregnant and not pregnant 15-19 weeks old, chow-fed IL1β KO mice and littermate controls; 
wild type n=24; IL-1β KO n=17; wild type pregnant n=9; IL-1β KO pregnant n=13; data of 6 cohorts. 
A: Glucose tolerance; B: Corresponding plasma insulin; C: Fasting blood glucose; D: Insulinogenic 
index; all data as mean ± SEM; statistics: 2-way ANOVA for repeated measurements and Holm-
Sidak multiple comparisons; * = wild type vs wild type pregnant; + = wild type pregnant vs. IL-1β 
KO pregnant
C D
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Figure 10
A-D: Quantification of histological data of pancreatic 
islets in healthy pregnant mice. Each dot represents 
the average of 6-13 serial sections thoughout the 
pancreas of one mouse in 100µm distance; control 
n=3 mice, 31 sections; anti-IL-1β n=2 mice, 19 
sections; pregnant n=2 mice, 24 sections; anti-IL-1β 
pregnant n=4 mice, 45 sections; E-G: Islet gene 
expression of proliferation markers in healthy 
pregnant mice, E and F: Control n=10, anti-IL-1β 
n=10, pregnant n=13, anti-IL-1β pregnant n=13, 
data from 3 cohorts; G: Control n=6, anti-IL-1β n=6, 
pregnant n=9, anti-IL-1β pregnant n=9, data from 2 
cohorts; all data as mean ± SEM
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Figure	11	
A	 B	
C	 D	
Figure	11	
Representa)ve	pictures	of	sec)ons	through	the	middle	of	the	pancreas	of	chow	fed,	pregnant	and	
not	pregnant	mice	treated	with	an)-IL-1β	or	vehicle:	A:	Control,	B:	An)-IL-1β	C:	Pregnant	D:	An)-
IL-1β;	blue:	nuclei	stained	with	DAPI,	green:	insulin	stained	with	FITC		
		
pronounced.	The	number	of	insulin-producing	ductal	cells	per	µm2	pancreas	area	was	similar	in	pregnant	mice	and	controls	(Fig.	10).		Anti-IL-1β	didn’t	influence	β-cell	area,	average	islet	size	or	number	of	islets.	But	there	is	a	clear	trend	for	less	insulin-producing	ductal	cells	in	non-pregnant	anti-IL-1β-treated	mice.	The	 histological	 data	 were	 complemented	 by	 the	 measurement	 of	 the	 gene	expression	of	the	proliferation	markers	Mki67,	Pcna	and	Ccna2	in	isolated	islets	of	12-22	weeks	 old	 chow-fed	mice	 (Fig	 10).	 There	was	 no	 difference	 in	 the	 gene	expression	of	Pcna	 and	Ccna2,	 but	 there	was	a	 remarkable	 trend	 for	 increased	
Mki67	expression	in	the	islets	of	pregnant	mice,	which	was	reduced	with	anti-IL-1β	treatment.	
	
Insulin	tolerance	of	healthy	pregnant	mice		To	 test	 if	 IL-1β	 has	 an	 influence	 on	 insulin	 tolerance	 in	 pregnant	mice	 and	 to	further	 characterize	 the	 glucose	 metabolism	 of	 pregnant	 mice	 we	 performed	insulin	tolerance	tests	in	the	healthy	pregnancy	model	(Fig.	12).	In	these	tests	the	blood	glucose	of	mice	was	measured	prior	to	and	15,	30,	60,	90	and	120	minutes	after	the	subcutaneous	injection	of	an	insulin	bolus.		We	didn’t	detect	a	difference	in	insulin	tolerance	in	pregnant	mice	compared	to	non-pregnant	 controls.	 Anti-IL-1β	 neither	had	 an	 effect	 on	 insulin	 tolerance	 of	pregnant	mice	nor	on	that	of	non-pregnant	control	mice.		
	 35	
	
Organ	weight	and	fetal	weight	in	pregnant	mice	with	anti-IL-1β	At	sacrifice	on	day	14.5	of	pregnancy,	the	liver,	spleen	and	adipose	tissue	pads	of	the	dams	were	weighed	(Fig.	13).	Pregnant	GDM	mice	had	enlarged	livers	and	spleens,	but	the	weight	of	the	adipose	tissue	was	similar	 to	 that	of	 the	high-fat	diet-fed	controls.	Anti-IL-1β	treatment	didn’t	influence	the	weight	of	the	organs	and	adipose	tissue	pads,	although	there	was	a	trend	for	a	slightly	reduced	liver	weight	in	the	pregnant	anti-IL-1β-treated	animals.			Less	data	was	acquired	for	healthy	pregnant	C57BL6/N	and	healthy	pregnant	15-20	weeks	old	IL-1β	KO	animals.	We	measured	the	weight	of	the	liver,	spleen	and	gonadal	adipose	tissue	in	the	wild	type	strain,	and	the	weight	of	the	liver	in	
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Figure 12
A: Insulin tolerance of 11-13 weeks old chow fed mice; control n=23; anti- IL-1β  n=14; pregnant n=9; 
anti-IL-1β pregnant n=8; data of 2 cohorts. B: Insulin tolerance of 16-18 weeks old chow fed mice; 
control n=14; anti-IL-1β n=7; pregnant n=3; anti-IL-1β pregnant n=7; data of 2 cohorts.
All values are presented as mean ± SEM; statistics: 2-way ANOVA for repeated measurements and 
Holm-Sidak multiple comparisons.
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Figure 13
A-F: The weight of different organs and fad pads of GDM mice; 
G-I: The weight of liver, spleen and gonadal fat pads of healthy 
pregnant mice; J: The weight of the liver of healthy IL-1β KO 
mice, age of mice 15-19 weeks; Each dot represents the weight 
of the organ/ fat pads of one mouse; all data as mean ± SEM; 
statistics: Kruskal-Wallis test with Dunn’s multiple comparisons
Healthy Pregnancy Model
GDM-Model
Healthy pregnant IL-1β KO Mice
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Figure 14: Fetal weight
Figure 14
A, B and C: Fetal weight in GDM model: control n=16, anti-IL-1β n=7; D, E and F: Fetal weight in 15-18 weeks old healthy 
pregnant mice: control n=24, anti-IL-1β n=14; G, H and I: Fetal weight in 15-22 weeks old, healthy pregnant IL-1β KO mice: 
control n=9, IL-1β KO n=9; A, D and G: Average fetal weight; B, E and H: Total litter weight; C, F and I: Litter size
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D E F
G H I
GDM Model
Healthy Pregnancy model
Healthy Pregnant IL-1β KO Model 
		
the	IL-1β	KO	strain.	The	livers	and	spleens	of	healthy	pregnant	mice	were	enlarged	compared	 to	 controls,	but	not	 the	gonadal	 adipose	 tissue.	Anti-IL-1β	 treatment	and	genetic	IL-1β	deficiency	didn’t	affect	the	organ	weight.	
	In	GDM	animals	the	average	fetal	weight	per	dam	was	independent	of	the	anti-IL-1β	treatment	(Fig.	14).	The	litter	size	in	the	anti-IL-1β-treated	mice	was	lower	in	our	sample,	consequently	the	total	litter	weight	tended	to	be	lower	in	the	anti-IL-1β-treated	mice.	In	healthy	pregnant	mice,	the	average	fetal	weight	in	anti-IL-1β-treated	mice	was	higher	than	in	the	controls.	The	higher	average	fetal	weight	didn’t	translate	to	a	higher	total	litter	weight,	despite	the	same	litter	size.	The	average	fetal	weight,	the	total	 litter	 weight	 and	 litter	 size	 in	 IL-1β	 KO	 mice	 was	 not	 dependent	 of	 the	genotype.	
Serum	steroid	hormones	The	serum	concentration	of	several	steroid	hormones	was	measured	in	healthy	pregnant	mice	(Fig.	15-17)	of	one	cohort.	Serum	was	sampled	at	sacrifice,	between	8h	 and	 10h	 in	 the	 morning.	 The	 panel	 comprised	 corticosterone,	 11-dehydrocorticosterone,	 progesterone,	 17α-hydroprogesterone,	 aldosterone,	 11-deoxycorticosterone,	androstendione	and	testosterone.	All	 steroid	 hormones	were	 increased	 in	 pregnant	mice	 (Fig.	 15).	 Interestingly,	there	was	a	trend	for	a	reduced	serum	concentration	for	every	hormone	in	anti-IL-1β-treated	 pregnant	 mice.	 The	 difference	 of	 the	 hormone	 concentrations	between	non-pregnant	anti-IL-1β-treated	and	pregnant	anti-IL-1β-treated	mice	were	not	significant	for	any	hormone.		The	trend	for	a	reduced	serum	concentration	in	anti-IL-1β-treated	pregnant	mice	was	most	pronounced	in	11-deoxycorticosterone.		When	the	serum	concentrations	of	the	steroid	hormones	are	plotted	to	the	litter	size,	linear	regression	shows	that	for	some	hormones,	the	litter	size	and	the	serum	hormone	concentrations	correlate	(Fig.	16).		
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Figure 15: Serum Steroid Hormones
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Figure 15
Serum steroid hormon concentrations during pregnancy with and without IL-1β antagonization: 
mineralocorticoids: A: 11-dehydrocorticosteone, E: Aldosterone, F: 11-deoxycorticosterone; 
glucocorticoid: B: Corticosterone; gestagens: C: Progesterone, D: 17α-hydroxyprogesterone; 
androgens: G: Androstendion and H: Testosterone; data of 1 cohort, chow fed, 12-16 weeks old; control 
n=8, anti-IL-1β n=3, pregnant n=7, anti-IL-1β pregnant n=11; all data as mean ± SEM, statistics: Kruskal-
Wallis test with Dunn’s multiple comparisons.  
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Figure 16
Serum steroid hormon concentrations on y-axis in relation to littersize on x-axis, with and without IL-1β 
antagonization: mineralocorticoids: A: 11-dehydrocorticosteone: control R2=0.7213, p=0.0324, E: 
Aldosterone: control R2=0.6558, p=0.0508 , F: 11-deoxycorticosterone: control R2=0.3088, p=0.2522; 
glucocorticoid: B: Corticosterone control R2=0.6547, p=0.0512; gestagens: C: Progesterone: control 
R2=0.7162, p=0.0336, D: 17α-hydroxyprogesterone: control R2=0.04819, p=0.676; androgens: G: 
Androstendion: control R2=0.1194, p=0.5023 H: Testosterone: control R2=0.3274, p=0.2097; data of 1 
cohort, chow fed, 12-16 weeks old; control n=8, anti-IL-1β n=3, pregnant n=7, anti-IL-1β pregnant n=11; 
all data as mean ± SEM, statistics: linear regression analysis
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Steroid	 hormones	 are	 generated	 from	 other	 steroid	 hormones	 [104].	 A	comparison	of	the	ratio	of	a	hormone	and	its	precursor	between	treatment	groups	indicates	if	the	enzyme	that	does	the	transformation	is	regulated	by	the	treatment.	Therefore,	we	calculated	the	ratios	of	the	steroid	hormones	that	we	measured	(Fig.	17).		The	 ratio	 of	 aldosterone	 to	 its	 precursors	 corticosterone	 and	 11-deoxycorticosterone	 was	 neither	 altered	 by	 pregnancy	 nor	 by	 anti-IL-1β	treatment.	 The	 ratio	 of	 corticosterone	 and	 11-dehydrocorticosterone	was	 also	similar	in	every	condition.	All	calculated	ratios	of	progesterone	were	changed	by	pregnancy.		Furthermore,	 there	was	 a	 trend	 for	 a	 regulation	 by	 anti-IL-1β	 of	 the	 ratios	 of	progesterone	 and	 aldosterone,	 corticosterone	 and	 11-deoxycorticosterone	respectively,	 always	 in	 favor	of	 relatively	more	progesterone	 in	 the	anti-IL-1β-treated	conditions,	independent	of	pregnancy.			
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Figure 17
Ratios of serum steroid hormon concentrations during pregnancy, with and without IL-1β antagonization: 
A: Aldosterone/ corticosterone, B: Aldosterone /11-deoxycorticosterone, C: Corticosterone/ 11-
deoxycorticosterone, D: Aldosterone/ prgogesterone, E: Corticosterone/ progesterone, F: Progesterone/ 
11-deoxycorticosterone, G: Progesterone/ 17α-hydroxyprogesterone, H: Corticosterone/ 11-
dehydrocorticosterone; data of 1 cohort, chow-fed, 12-16 weeks old; control n=8, anti-IL-1β n=3, 
pregnant n=7, anti-IL-1β pregnant n=11; all data as mean ± SEM, statistics: Kruskal-Wallis test with 
Dunn’s multiple comparisons; I: Map of steroid hormone synthesis adapted from the KEGG library [104]: 
bold: measured hormones, blue: enzymes katalysing the reaction indicated by the arrow. 
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	Also,	 the	 ratio	 of	 corticosterone	 and	 11-deoyxcorticosterone	 is	 influenced	 by	pregnancy,	and	there	is	a	trend	for	relatively	more	corticosterone	relative	to	11-deoxycorticosterone	in	pregnant	anti-IL-1β-treated	mice.			To	investigate	if	the	trend	for	altered	enzyme	activity	in	anti-IL-1β-treated	mice	is	due	to	altered	gene	expression	of	the	respective	enzymes	we	measured	the	gene	expression	of	Cyp21a1	and	Cyp11b1	and	Cyp11b2	in	the	placenta,	the	adrenals	and	the	ovaries	of	healthy	pregnant	dams	and	dams	with	GDM	(Fig.	18).	There	was	no	significant	 difference	 in	 the	 gene	 expression	 between	 controls	 and	 anti-IL-1β-treated	mice.	With	anti-IL-1β	treatment,	there	were	trends	for	reduced	Cyp11b1	expression	in	the	placenta	of	healthy	pregnant	mice	and	the	
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	ovaries	of	healthy	pregnant	and	GDM	mice,	reduced	Cyp11b2	expression	in	the	ovaries	of	healthy	pregnant	mice	and	the	adrenals	of	GDM	mice	and	reduced	
Cyp21a1	expression	in	placentas	of	GDM	mice.		
	
LysMCreIL-1β	KO	model	To	test	if	the	IL-1β	that	influenced	glucose	tolerance	of	pregnant	mice	derives	from	cells	of	 the	myeloid	lineage,	we	mated	high-fat	diet-fed	LysMCre-IL-1β	KO	mice	and	 their	 littermate	 controls.	 The	 data	 of	 this	 experiment	 derive	 from	 three	glucose	 tolerance	 tests	 with	 one	 mouse	 cohort,	 which	 was	 mated	 repeatedly.	Therefore,	 the	age	of	 the	mice	ranged	between	11	and	18	weeks	(Fig.	19).	The	glucose	tolerance	of	pregnant	wild	type	mice	was	impaired	compared	that	of	wild	type	controls,	and	they	had	higher	plasma	insulin	levels.	LysMCre-IL-1β	KO	mice	tended	 to	have	an	 improved	glucose	 tolerance	 compared	 to	wild	 type	 controls,	both	 in	 pregnant	 and	 in	 non-pregnant	 mice.	 In	 non-pregnant	 controls,	 the	improvement	of	glucose	tolerance	of	LysMCre-IL-1β	KO	mice	was	significant.		The	plasma	insulin	of	LysMCre-IL-1β	KO	mice	tended	to	be	 lower,	both	 in	pregnant	and	in	non-pregnant	mice.	Fasting	blood	glucose	and	the	insulinogenic	index	were	not	different.	
Figure 18
Gene expression of Cyp11b1, Cyp11b2 and Cyp21a1 in placenta, ovaries and adrenals expressed as 
fold of control relative to the reference genes Actinb and Gapdh. A-C: Placental gene expression in 
healthy pregnant mice: control n=9, anti-IL-1β n=11; D-F: Placental gene expression in GDM model: 
control n=14, anti-IL-1β n=5; G-I: Ovarian gene expression in healthy pregnant mice: control: n=6, anti-
IL-1β: n=6, control pregnant: n=4, anti-IL-1β pregnant: n=4; J-L: Ovarian gene expression in GDM mice: 
control: n=6, anti-IL-1β: n=4,  control pregnant: n=11, anti-IL-1β  pregnant: n=5, M-O: Adrenal gene 
expression in GDM mice: control: n=4, anti-IL-1β: n=4, control pregnant: n=8, anti-IL-1β pregnant: n=2, all 
data as mean ± SEM. 
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Figure 19: Glucose tolerance of LysMCre-IL1β KO mice with GDM 
Figure 19
A-D: 11-18 weeks old, HFD fed, pregnant and not pregnant LysMCre-IL1β KO mice and 
littermate controls:
A: Glucose tolerance; B: Corresponding Insulin; C: Fasting Glucose; D: Insulinogenic index, wild 
type: n=18, LysMCre-IL-1β KO: n=20, wild type pregnant: n=5, LysMCre-IL1β KO pregnant: n=4; 
data as mean ± SEM, statistics: A, B: 2way ANOVA with Holm-Sidak multiple comparisons; * = 
wild type vs. wild type pregnant, # = wild type vs. LysMCre-IL1β KO
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Discussion	
A	mouse	model	of	gestational	diabetes	On	day	13.5	of	normal,	healthy	mouse	pregnancies,	glucose	tolerance,	tested	by	subcutaneous	 glucose	 tolerance	 tests,	 was	 impaired	 and	 insulin	 secretion	was	increased	in	10-13	weeks	old	as	well	as	in	15-18	weeks	old	mice.	These	results	are	in	line	with	i.p.	glucose-tolerance	tests	performed	in	pregnant	mice	on	day	16.5	[25,	105].		Insulin	 secretion	of	 pregnant	mice	was	 increased	 basally	 as	well	 as	 during	 the	tests,	 while	 glucose	 tolerance	 was	 impaired.	 This	 indicates	 that	 the	 glucose-stimulated	insulin	secretion	of	pregnant	mice	was	not	increased	compared	to	that	of	control	mice,	which	is	also	illustrated	by	the	insulinogenic	index.	The	impaired	glucose	tolerance,	concurrent	with	the	increased	insulin	secretion	is	indicative	for	the	expected	insulin	resistance	during	pregnancy	[25].		The	age	of	the	mice	didn’t	change	the	glucose	phenotype.	We	speculate	that	15-18	weeks	are	not	old	enough	to	model	high	maternal	age-induced	GDM.				High-fat	diet	feeding	led	to	pronounced	glucose-tolerance	impairment	in	pregnant	mice	compared	to	non-pregnant	controls.	This	occurred	when	mice	received	the	high-fat	 diet	 either	 only	 during	 pregnancy,	 or	 already	 before	 the	 onset	 of	pregnancy.	The	peak	plasma	glucose	concentration	in	pregnant	animals	was	at	30	minutes	after	glucose	injection	instead	of	after	15	minutes	in	chow-fed	pregnant	and	 control	mice.	 Late	 blood	 glucose	 peaks	 during	 glucose-tolerance	 tests	 are	commonly	observed	in	insulin	resistant	animals	[106-109].		Pregnant	mice,	which	received	high-fat	diet	feeding	only	during	pregnancy,	had	highly	 increased	 insulin	 secretions,	 which	 might	 partly	 compensate	 for	 the	presumably	 increased	 insulin	 resistance.	 In	 contrast,	 pregnant	 mice,	 which	received	 high-fat	 diet	 already	 before	 pregnancy	 were	 not	 able	 to	 mount	 a	sufficiently	 high	 insulin	 response.	 Their	 plasma	 insulin	 was,	 despite	 impaired	glucose	tolerance,	not	higher	than	that	of	the	non-pregnant	controls,	suggesting	β-cell	failure.	The	insulinogenic	index	of	pregnant	mice	and	control	mice	was	equal	in	both	groups,	but	it	was	higher	in	mice,	which	received	high-fat	diet	only	for	a	
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short	time	during	pregnancy	than	in	those	which	received	high-fat	diet	for	a	longer	period,	which	also	reflects	the	impaired	insulin	response	in	the	latter.			Based	on	our	data,	together	with	the	known	risk	for	obese	women	to	develop	GDM,	we	conclude	that	high-fat	diet	feeding	with	onset	before	pregnancy	in	relatively	old	mice	is	a	good	model	to	study	GDM.	When	 the	 data	 of	 all	 four	 models	 tested	 are	 taken	 into	 account,	 the	 glucose-tolerance	impairment	during	pregnancy	correlated	with	the	weight	of	the	mouse	before	pregnancy.	This	further	supports	the	model.			However,	there	are	also	limitations	to	the	high-fat	diet-induced	GDM	model.	The	fasting	blood	glucose	of	the	pregnant	mice	was	not	increased	compared	to	that	of	non-pregnant	control	mice.		And,	more	important,	the	fetal	weight	of	dams	fed	high-fat	diet	was	not	increased	compared	to	that	of	dams	fed	normal	chow.	This	might	be	explained	by	the	slightly	increased	 litter	size	 (the	more	 fetuses	 there	are,	 the	 lower	 is	 the	weight	of	 the	average	 fetus	 [110])	of	our	sample,	but	also	 to	 the	gestational	 age.	The	day	on	which	we	sacrificed	the	animals	was	at	the	beginning	of	the	third	trimester,	which	is	the	important	phase	of	fetal	weight	gain	[111].	In	a	study	performed	on	day	18.5	of	pregnancy,	high-fat	diet	increased	the	fetal	weight	in	C57BL/6	mice	[112].	This	discrepancy	to	our	results	may	also	be	explained	by	a	different	composition	of	the	high-fat	 diet	 used.	 It	 contained	 larger	 proportion	 of	 calories	 coming	 from	carbohydrates	than	our	high-fat	diet.		High-fat	diet	 feeding	 influenced	 the	 fertility	of	 the	mice:	There	was	a	 trend	 for	more	mice	becoming	pregnant	during	timed	mating	 in	high-fat	diet-fed	cohorts	compared	to	chow-fed	cohorts.	This	may	stem	from	altered	sex	hormone	levels	as	described	by	Whyte	et	al.	 [113].	 It	has	been	 reported	 that	high-fat	diet	 feeding	reduces	fertility	[114],	but	in	many	studies	also	male	mice	received	high-fat	diet	for	which	 a	 reduced	 fertility	with	 high-fat	 diet	 has	 been	 reported	 [115].	 Other	explanations	 could	 be	 the	 composition	of	our	high-fat	 diet	 and	 the	 duration	 of	high-fat	diet	feeding	before	mating.		
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In	the	following	sections,	the	model	with	19-20	weeks	old	mice	and	high-fat	diet	feeding	before	and	during	pregnancy	will	be	called	GDM	model,	the	model	with	10-18	weeks	old,	chow-fed	mice	will	be	called	healthy-pregnancy	model.		We	 hypothesized,	 that	 increased	 IL-1β	 contributes	 to	 the	 glucose	 intolerance	during	pregnancy	and	 in	GDM.	 Indeed,	 serum	IL-1β	was	 increased	 in	pregnant	mice,	 both	 in	 healthy	 pregnancy	 and	 in	 the	 short-term	 high-fat	 diet	 model.	However,	the	difference	was	not	detectable	when	the	mice	were	fasted,	which	is	the	case	before	glucose-tolerance	testing.	But	IL-1β	is	a	highly	potent	cytokine,	of	which	 locally	 high	 concentrations	 can	 have	 important	 effects,	 without	 a	systemically	detectable	difference	or	without	being	detectable	at	all	[116].	Thus	IL-1β	might	influence	glucose	tolerance	during	pregnancy	also	in	fasted	mice.	Consequently,	we	measured	Il1b	gene	expression,	in	organs	where	we	suspected	a	difference	between	pregnant	and	non-pregnant	mice:	In	organs	that	influence	the	 glucose	metabolism	 such	 as	 pancreatic	 islets	 and	 the	 insulin-target	 tissues	liver,	muscle	and	subcutaneous	adipose	tissue,	in	peripheral	blood	cells	and	in	the	uterus	with	the	fetal-maternal	interface.		We	found	higher	Il1b	gene	expression	in	the	uterus	of	pregnant	GDM	mice,	and	a	trend	for	higher	Il1b	gene	expression	in	the	uterus	of	healthy	pregnant	mice.	Il1b	gene	 expression	 normalized	 to	 the	 expression	 of	 18s	 in	 the	 uterus	 may	 even	underestimate	the	real	increase	during	pregnancy,	as	also	the	18s	expression,	as	well	as	the	expression	of	10	other	reference	genes	(we	show	Actinb	and	Gapdh)	was	increased.	This	underlines	the	difference	of	a	normal	uterus	and	the	modified	uterus	during	pregnancy.	If	the	concentration	of	active	IL-1β	protein	is	increased	in	the	uterus	of	pregnant	mice,	 and	 if	 this	 can	 contribute	 to	 increased	 systemic	 IL-1β	 remains	 to	 be	investigated.			
Blocking	IL-1β	signaling	improves	glucose	tolerance	of	pregnant	mice	The	best	way	to	test	if	IL-1β	has	an	effect	on	a	parameter	like	glucose	tolerance,	is	to	antagonize	it	and	measure	the	parameter	without	it	[116].	Blocking	IL-1β	by	injecting	anti-IL-1β	during	 the	 second	 trimester	 improved	glucose	 tolerance	of	
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pregnant	mice	of	the	GDM	model	and,	to	a	lesser	extent,	of	the	healthy	pregnancy	model.	The	latter	was	supported	by	experiments	with	IL-1β	KO	mice,	which	are	constitutively	 IL-1β-deficient	 and	 not	 only	 during	 the	 second	 trimester	 of	pregnancy.		The	glucose	tolerance	of	the	non-pregnant	control	mice	was	not	improved	by	IL-1β	 antagonism	 or	 deficiency,	 suggesting	 a	 pregnancy-specific	 IL-1β	 effect.	 The	control	 mice	 in	 the	 GDM	 model	 received	 high-fat	 diet,	 thus	 the	 pregnancy	specificity	 is	 in	 conflict	 with	 studies	 showing	 that	 IL-1β	 antagonism	 or	 IL-1β	deficiency	improves	glucose	tolerance	in	high-fat	diet-fed	mice	[106,	107].	These	studies	examined	male	mice,	which	are	more	susceptible	to	diet-induced	obesity	and	 impaired	 glucose	 control	 than	 females	 [117].	 This	 sex	 difference	 and	 the	duration	and	different	compositions	of	the	diets	used	in	[106,	107]	compared	to	our	high-fat	diet	might	explain	the	discrepancy.	Since	 the	 glucose	 tolerance	 of	 anti-IL-1β-treated	 and	 IL-1β-deficient	 pregnant	mice	 was	 only	 partially	 restored	 and	 still	 impaired	 compared	 to	 that	 of	 non-pregnant	controls,	it	is	evident	that	IL-1β	cannot	be	the	only	trigger	for	pregnancy-induced	glucose	intolerance.	Insulin	secretion	of	pregnant	mice	of	the	GDM	model	and	the	healthy	pregnancy	model	 was	 not	 significantly	 improved	 by	 anti-IL-1β	 treatment,	 but	 the	insulinogenic	index	of	pregnant	anti-IL-1β-treated	mice	of	the	GDM	model	tended	to	 be	 improved	 compared	 to	 that	 of	 the	 not	 treated	mice,	 pointing	 to	 a	 better	insulin	response	to	the	glucose	stimulus.	The	insulin	secretion	of	healthy	pregnant	IL-1β	KO	mice	was	notably	higher	than	that	of	littermate	controls.	This	may	be	due	to	the	fact	that	the	IL-1β	deficiency	in	the	IL-1β-KO	mice	was	already	present	before	and	at	the	beginning	of	pregnancy,	influencing	 the	 capability	 of	 the	 pancreatic	 islets	 to	 adapt	 to	 stressors	 like	pregnancy.	 The	 mean	 insulinogenic	 index	 in	 the	 pregnant	 IL-1β-KO	mice	 was	better,	although	not	statistically	significant	with	our	sample	size.			In	 summary,	 neutralizing	 IL-1β	 and	 genetic	 IL-1β	 deficiency	 improved	 glucose	tolerance	in	pregnant	mice,	and	this	beneficial	effect	was	even	more	pronounced	in	GDM.	The	improvement	was	specific	for	pregnancy	and	didn’t	occur	in	high-fat	diet-fed	 control	 mice,	 which	 were	 glucose	 intolerant	 compared	 to	 chow-fed	
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control	mice.	The	effect	of	 IL-1β	antagonism	might	be	achieved	 through	better	insulin	secretion,	thus	an	effect	on	pancreatic	β	cells.	However,	the	effect	on	insulin	secretion	was	mild	in	the	anti-IL-1β-treated	mice,	suggesting	additional	effects	on	either	insulin	sensitivity	of	the	mother	or	on	glucose	transfer	to	the	fetus.		
β-Cell	mass		Higher	 insulin	 secretion	during	pregnancy	 is	 the	 function	of	higher	β-cell	mass	[32].	 Assuming	 that	 anti-IL-1β	 treatment	 influences	 insulin	 secretion,	 we	 may	hypothesize	 that	 anti-IL-1β	 treatment	 increases	 β	 cell-mass	 expansion	 during	pregnancy.	Moreover,	IL-1β	antagonism	with	XOMA	052,	a	neutralizing	anti-IL-1β	antibody,	increased	β-cell	mass	in	high-fat	diet-fed	mice	through	increased	β-cell	proliferation	and	decreased	β-cell	apoptosis	[106].	In	contrast	to	this,	we	didn’t	observe	an	increase	of	β-cell	mass	(expressed	as	β-cell	 area/pancreatic	 area	 on	 histological	 sections)	 in	 healthy	 pregnant	 mice	treated	with	anti-IL-1β	compared	to	pregnant	control	mice.		Ki-67	 is	a	commonly	used	proliferation	marker.	 It	 is	associated	with	ribosomal	RNA	transcription	[118].	In	islets	isolated	from	pregnant	mice	during	the	second	trimester	(day	10.5	and	14.5),	the	gene	expression	of	Mki67,	the	gene	encoding	for	Ki-67,	is	increased,	probably	reflecting	the	increased	β-cell	proliferation	[119].	We	saw	an	increased	gene	expression	of	Mki67	in	islets	of	healthy	pregnant	mice	as	well.	However,	in	islets	isolated	from	anti-IL-1β-treated	pregnant	mice	the	Mki67	gene	expression	was	unexpectedly	reduced	to	the	levels	of	non-pregnant	controls.		More	studies	about	β-cell	mass	and	β-cell	proliferation	in	the	GDM	model	and	in	IL-1β	KO	mice	will	be	needed	to	clarify	the	role	of	IL-1β	in	pregnancy-induced	β	cell-mass	expansion.		
Insulin	tolerance,	organ	weight	and	fetal	weight	To	test	if	antagonizing	IL-1β	has	an	effect	on	insulin	sensitivity	during	pregnancy	we	 performed	 insulin-tolerance	 tests	 in	 healthy	 pregnant	mice	 on	 day	 13.5	 of	pregnancy.	 In	 contrast	 to	studies	done	on	day	16.5	of	pregnancy	 [25,	105],	we	didn’t	 see	 pregnancy-induced	 insulin	 resistance	 using	 insulin-tolerance	 tests.	
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Consequently,	we	 cannot	 conclude	 on	 an	 effect	 of	 IL-1β	 antagonism	on	 insulin	sensitivity	with	this	test.			Since	insulin	regulates	cell	growth	and	glycogen	and	lipid	storage,	a	difference	in	insulin	sensitivity	might	influence	the	weight	of	organs.	We	measured	the	weight	of	various	organs	and	adipose	tissue	pads	in	pregnant	mice	of	the	GDM	model	and	healthy	 pregnant	 mice	 with	 and	 without	 anti-IL-1β	 treatment.	 We	 saw	 the	expected	 pregnancy-induced	weight	 increase	 of	 the	 liver	 [120]	 and	 the	 spleen	[121],	but	there	was	no	pregnancy-induced	weight	gain	of	the	subcutaneous	and	the	gonadal	adipose	tissue,	which	has	been	reported	by	Zhang	et	al.	 [122].	The	weight	of	the	gonadal	adipose	tissue	and	the	mesenterium	(containing	the	visceral	adipose	tissue)	was	even	decreased	in	pregnant	mice	of	the	GDM	model	compared	to	the	respective	non-pregnant	controls.	This	may	be	due	to	the	insulin	resistance-induced	increased	lipolysis	[123].	IL-1β	antagonism	didn’t	reveal	effects	on	organ	weights	with	the	sample	size	analyzed.		The	fetus	is	an	important	glucose	sink	in	the	body	of	the	mother.	The	improvement	of	 glucose	 tolerance	with	 IL-1β	 antagonism	 could	 be	 due	 to	 increased	 glucose	clearance	by	the	placental-fetal	unit.	To	approach	this,	we	measured	fetal	weight.	The	average	fetal	weight	of	healthy	pregnant	mice	was	indeed	higher	in	anti-IL-1β-treated	 mice,	 but	 this	 difference	 was	 not	 large	 enough	 to	 translate	 into	increased	total	litter	weight.	In	the	mice	of	the	GDM	model	and	in	IL-1β-KO	mice,	there	was	no	difference	in	fetal	weight.		More	studies	will	be	needed	to	look	at	insulin	sensitivity	and	fetal	glucose	uptake	in	pregnant	mice	treated	with	anti-IL-1β.			
Serum	steroid	hormones		Steroid	hormones	 contribute	 to	 pregnancy-induced	 insulin	 resistance	 [28]	 and	might	be	 regulated	by	 IL-1β	 [65-69].	We	 therefore	measured	a	panel	of	 serum	steroid	 hormone	 concentrations	 in	 pregnant	mice	with	 and	without	 anti-IL-1β	treatment.	We	did	this	in	the	healthy-pregnancy	model	in	the	morning	(8.30-9.30	a.m.).		
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All	 hormones	 measured	 were	 increased	 during	 pregnancy	 compared	 to	 non-pregnant	 controls.	 Interestingly,	 IL-1β	 antagonism	 tended	 to	 reduce	 all	 steroid	hormone	concentrations.		The	 concentrations	 of	 corticosterone,	 progesterone,	 11-dehydrocorticosterone	and	11-deoxycorticosterone	correlated	with	the	litter	size,	suggesting	that	these	hormones	 were	 predominantly	 produced	 by	 the	 placental-fetal	 unit.	 The	correlation	 of	 maternal	 serum	 corticosterone	 levels	 and	 litter	 size	 has	 been	described	before	[124].	However,	it	has	been	published	that	in	pregnant	mice,	progesterone	is	a	product	of	the	ovaries	(with	one	corpus	luteum	per	fetus)	[125],	where	their	secretion	is	stimulated	 by	 placental	 lactogen	 I	 and	 II,	 and	 corticosterone	 a	 product	 of	 the	maternal	adrenals	 [126,	127].	Nevertheless,	 the	placenta	 is	able	 to	produce	the	hormones	mentioned	above	and	contributes	to	their	high	serum	concentrations	during	pregnancy	[127-129].		With	anti-IL-1β	treatment,	the	ratio	of	progesterone	to	every	other	hormone	was	tilted	toward	more	progesterone,	also	in	the	non-pregnant	control	mice.	The	ratio	of	11-deoxycorticosterone	to	corticosterone	was	tilted	toward	corticosterone.	The	ratios	 of	 corticosterone	 to	 aldosterone	 and	 11-dihydrocorticosterone	 were	neither	influenced	by	pregnancy,	nor	by	anti-IL-1β	treatment.	This	suggests	that	IL-1β	downregulated	the	conversion	of	progesterone	to	11-deoxycorticosterone	and	upregulated	the	conversion	of	11-deoxycorticosterone	to	corticosterone.		Progesterone	and	corticosterone	have	been	associated	with	pregnancy-induced	insulin	 resistance	 [25,	 28],	 therefore	 tilting	 the	 ratios	 to	 relatively	 more	progesterone	 and	 corticosterone	 in	 anti-IL-1β-treated	 mice	 cannot	 explain	 an	improvement	 of	 their	 glucose	 tolerance.	 However,	 11-deoxicorticosterone	 is	known	to	induce	gluconeogenesis	and	reduce	insulin	sensitivity	in	rats	[130].	It	may	be	that	the	relative	increase	in	progesterone	and	corticosterone	is	rather	a	relative	 decrease	 in	 11-deoxycorticosterone.	 In	 absolute	 values	 all	 three	hormones	were	reduced	in	anti-IL-1β-treated	animals.	We	tested	if	anti-IL-1β	treatment	influences	the	gene	expression	of	the	enzymes	responsible	 for	 the	conversions	of	progesterone	to	11-deoxycorticosterone	and	11-deoxycorticosterone	to	corticosterone	in	the	placenta,	the	maternal	adrenals	and	 the	maternal	 ovaries	 analogue.	 In	 pregnant	 anti-IL-1β-treated	mice	 of	 the	
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healthy	pregnancy	and	GDM	model,	we	observed	trends	for	reduced	expression	of	
Cyp11b1	 and	 Cyp11b2	 (encoding	 for	 steroid-11β-hydroxylase,	 which	 is	responsible	 for	 the	 conversion	of	 11-deoxycorticosterone	 to	 corticosterone)	 in	several	organs.	This	does	not	fit	to	relatively	less	11-deoxycorticosterone	in	anti-IL-1β-treated	mice.	We	also	observed	a	trend	for	reduced	expression	of	Cyp21a1	(encoding	for	steroid-21-hydroxylase,	which	is	responsible	for	the	conversion	of	progesterone	 to	 11-deoxycorticosterone)	 in	 the	 placentas	 of	 GDM	mice,	 which	would	 fit	 to	 relatively	 less	 11-deoxycorticosterone.	 Collectively	 the	 data	 on	
Cyp11b1,	 Cyp11b2	 and	 Cyp21a1	 gene	 expression	 do	 not	 indicate	 that	 IL-1β	regulates	 steroid	 hormone	 synthesis	 through	 direct	 influence	 on	 the	 gene	expression	of	the	involved	enzymes.	In	 summary,	 we	 observed	 increased	 serum	 steroid	 hormone	 concentrations	during	 pregnancy	 and	 trends	 for	 reduced	 steroid	 hormone	 concentrations	 in	healthy	pregnant	mice	treated	with	anti-IL-1β.	We	assume	that	the	placenta	either	directly	or	indirectly	regulates	the	production	of	these	steroid	hormones,	and	that	the	placenta	 is	 therefore	 the	place	where	 IL-1β	most	probably	exerts	an	effect	during	pregnancy.	However,	 it	 is	unlikely	 that	IL-1β	directly	regulates	 the	gene	expression	of	the	enzymes	involved	in	the	steroid	synthesis.		More	studies	are	needed	to	find	causal	relations	between	IL-1β,	steroid	hormone	synthesis	 and	 glucose	 metabolism	 during	 pregnancy.	 An	 important	 steroid	hormone	missing	 in	our	panel	 is	 estradiol,	which	at	high	 levels	 induces	 insulin	resistance,	but	at	lower	levels	preserves	insulin	sensitivity	[57].		In	addition,	measuring	the	concentrations	of	placental	lactogen	I	and	II	might	be	of	interest,	as	they	are	known	to	regulate	progesterone	secretion	from	the	ovaries	during	mouse	pregnancy	[125].	Furthermore,	IL-1	signaling	stimulates	the	release	of	pituitary	prolactin	and	growth	hormone	 in	rats	 [69].	Prolactin	and	placental	lactogen	are	closely	related	hormones,	acting	on	the	same	receptor	[131].			
LysMCre-IL-1β	KO	model	Many	cell	types	are	able	to	produce	IL-1β,	i.a.	 leukocytes	of	the	myeloid	lineage	like	macrophages	and	monocytes	[132,	133].	If	myeloid-cell	derived	IL-1β	plays	a	role	in	GDM	was	tested	with	a	mouse	strain	where	myeloid	lineage	cells	are	IL-1β	
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deficient:	The	LysMCre-IL-1β	KO	strain.	High-fat	diet-fed	LysMCre-IL-1β	KO	mice	had	 improved	 glucose	 tolerance	 compared	 to	 their	 littermate	 controls,	independent	of	pregnancy.		Interestingly,	the	plasma	insulin	levels	of	the	LysMCre-IL-1β	KO	mice	tended	to	be	lower	than	that	of	wild	type	mice,	hinting	to	a	decrease	of	insulin	resistance	and	not	to	an	increase	of	β-cell	function.	These	data	are	still	preliminary	and	have	to	be	confirmed	in	independent	cohorts	with	the	same	settings	as	in	the	wild-type	GDM	model.	Nevertheless,	our	results	suggest	that	 that	 the	 lack	of	myeloid-cell	derived	IL-1β	protects	from	glucose	intolerance	during	pregnancy.	
	
Conclusion	In	this	study	we	show	that	 treating	mice	with	GDM,	and	healthy	pregnant	mice	with	an	anti-inflammatory	therapy	improves	their	glucose	tolerance.	Although	our	results	do	not	allow	final	conclusions,	we	propose	the	following	mechanism:		During	pregnancy,	immune	cells	of	the	myeloid	lineage	in	the	decidua,	close	to	the	maternal-fetal	interface,	produce	IL-1β.	The	cytokine	acts	on	the	placenta,	where	it	stimulates	the	production	of	steroid	hormones	and	possibly	the	production	of	other	placental	factors	which	induce	insulin	resistance	in	the	maternal	body	and	have	potentially	influence	on	the	pancreatic	insulin	response.		In	 GDM,	 the	 effect	 of	 IL-1β	 is	 enhanced	 in	 the	 course	 of	 the	 proinflammatory	changes	 in	 this	 disease.	 This	 supports	 the	 concept	 of	 GDM	as	 an	 inflammatory	disease.							
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